Anavex Life Sciences Corp.
AVXL
$2.75
-$0.10-3.51%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -13.02M | -34.09M | -39.95M | -46.38M | -48.17M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -11.94M | 9.47M | 10.60M | 11.55M | 9.90M |
| Change in Net Operating Assets | -4.33M | -8.04M | -4.73M | -4.22M | 1.17M |
| Cash from Operations | -29.29M | -32.66M | -34.08M | -39.04M | -37.10M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 46.90M | 47.02M | 47.76M | 12.14M | 1.77M |
| Repurchase of Common Stock | -445.00K | -2.71M | -2.71M | -2.71M | -2.26M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 46.45M | 44.31M | 45.05M | 9.43M | -494.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 17.16M | 11.65M | 10.97M | -29.61M | -37.59M |